Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$117.31 USD

117.31
4,236,832

-5.38 (-4.39%)

Updated May 10, 2024 04:00 PM ET

After-Market: $117.27 -0.04 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Stock Moves -0.37%: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $86.01, marking a -0.37% move from the previous day.

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

by Zacks Equity Research

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Mark Vickery headshot

Markets Pop on Bargain Hunting, Stronger Economy

by Mark Vickery

The small-cap Russell 2000, still under water over the past month, led the way higher today.

J&J (JNJ) to Report Q3 Earnings, Its First After Unit Spin-Off

by Zacks Equity Research

J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.

Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the closing of the recent trading day, Moderna (MRNA) stood at $102.76, denoting a -1.6% change from the preceding trading day.

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

by Zacks Equity Research

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

Alexandria (ARE) Receives Rating Affirmation From Moody's

by Zacks Equity Research

Underpinning Alexandria's (ARE) solid operating and financial performance, Moody's Investors Service reaffirms the company's credit ratings of Baa1 and maintains its outlook rating at stable.

The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna

by Zacks Equity Research

Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.

Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More

by Zacks Equity Research

Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.

Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study

by Zacks Equity Research

Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $104.26, marking a +1.14% move from the previous day.

Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab

by Zacks Equity Research

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

Alexandria (ARE) Expedites Delivery of Moderna's New HQ

by Zacks Equity Research

Alexandria (ARE) to hand over the new global headquarters and core R&D operations center to Moderna in November 2023. ARE will benefit from the project's incremental annual net operating income.

The Zacks Analyst Blog Highlights Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours

by Zacks Equity Research

Intel, Anheuser-Busch InBev, HCA Healthcare, Moderna and DuPont de Nemours are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Intel, Anheuser-Busch & HCA Healthcare

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Intel Corporation (INTC), Anheuser-Busch InBev SA/NV (BUD) and HCA Healthcare, Inc. (HCA).

Shaun Pruitt headshot

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

by Shaun Pruitt

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $100.27, marking a +0.83% move from the previous day.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $99.99, moving -0.24% from the previous trading session.

Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down

by Zacks Equity Research

Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed at $114.59 in the latest trading session, marking a +1.58% move from the prior day.

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

by Zacks Equity Research

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More

by Kinjel Shah

The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.

Company News for Sep 15, 2023

by Zacks Equity Research

Companies in The News Are: HPQ, BRK.B, SMTC, MRNA, CWK

Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data

by Zacks Equity Research

Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.